UBP608
featured

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 555175

CAS#: 2199-87-3

Description: UBP608 is NMDA receptor family allosteric modulator that selectively inhibits GluN1/GluN2A receptors with a 23-fold selectivity compared to GluN1/GluN2D receptors.


Price and Availability

Size Price Shipping out time Quantity
5mg USD 245 2 Weeks
25mg USD 545 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-10-30. Prices are subject to change without notice.

UBP608, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 555175
Name: UBP608
CAS#: 2199-87-3
Chemical Formula: C10H5BrO4
Exact Mass: 267.9371
Molecular Weight: 269.05
Elemental Analysis: C, 44.64; H, 1.87; Br, 29.70; O, 23.79


Synonym: UBP608; UBP-608; UBP 608.

IUPAC/Chemical Name: 6-Bromo-2-oxo-2H-chromene-3-carboxylic acid

InChi Key: XFQHPAXNKDYMOX-UHFFFAOYSA-N

InChi Code: InChI=1S/C10H5BrO4/c11-6-1-2-8-5(3-6)4-7(9(12)13)10(14)15-8/h1-4H,(H,12,13)

SMILES Code: O=C(C(C1=O)=CC2=C(O1)C=CC(Br)=C2)O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Monaghan DT, Irvine MW, Costa BM, Fang G, Jane DE. Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators. Neurochem Int. 2012 Sep;61(4):581-92. doi: 10.1016/j.neuint.2012.01.004. Epub 2012 Jan 17. Review. PubMed PMID: 22269804; PubMed Central PMCID: PMC3360989.

2: Irvine MW, Costa BM, Volianskis A, Fang G, Ceolin L, Collingridge GL, Monaghan DT, Jane DE. Coumarin-3-carboxylic acid derivatives as potentiators and inhibitors of recombinant and native N-methyl-D-aspartate receptors. Neurochem Int. 2012 Sep;61(4):593-600. doi: 10.1016/j.neuint.2011.12.020. Epub 2012 Jan 13. PubMed PMID: 22265875; PubMed Central PMCID: PMC3394894.

3: Costa BM, Irvine MW, Fang G, Eaves RJ, Mayo-Martin MB, Laube B, Jane DE, Monaghan DT. Structure-activity relationships for allosteric NMDA receptor inhibitors based on 2-naphthoic acid. Neuropharmacology. 2012 Mar;62(4):1730-6. doi: 10.1016/j.neuropharm.2011.11.019. Epub 2011 Dec 6. PubMed PMID: 22155206; PubMed Central PMCID: PMC3269548.

4: Costa BM, Irvine MW, Fang G, Eaves RJ, Mayo-Martin MB, Skifter DA, Jane DE, Monaghan DT. A novel family of negative and positive allosteric modulators of NMDA receptors. J Pharmacol Exp Ther. 2010 Dec;335(3):614-21. doi: 10.1124/jpet.110.174144. Epub 2010 Sep 21. PubMed PMID: 20858708; PubMed Central PMCID: PMC2993558.